Literature DB >> 16184176

Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.

M Weisser, C Schmid, C Schoch, W Hiddemann, H J Kolb.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16184176     DOI： 10.1038/sj.bmt.1705172

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  2 in total

1.  The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.

Authors:  Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich
Journal:  Blood       Date:  2006-10-24       Impact factor: 22.113

2.  Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia.

Authors:  Xavier Poiré; Andrew Artz; Richard A Larson; Justin Kline; Olatoyosi Odenike; Elizabeth Rich; Lucy Godley; Wendy Stock; Koen van Besien
Journal:  Leuk Lymphoma       Date:  2009-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.